Scott+Scott Attorneys at Law LLP Reminds Investors of the Class Action Against Iovance Biotherapeutics, Inc. (IOVA)

A securities class action has been filed against Iovance Biotherapeutics (IOVA) on behalf of investors who purchased shares between May 9, 2024, and May 8, 2025, alleging the company made misleading statements regarding the commercial launch of Amtagvi. Specifically, the lawsuit claims Iovance failed to disclose longer timelines for new Authorized Treatment Centers (ATCs) to begin treating patients, ineffective patient identification, and higher patient drop-offs, leading to increased costs and lower revenue. The news follows Iovance's announcement on May 8, 2025, of disappointing Q1 2025 revenue of $49.3 million and a slashed FY25 revenue guidance, causing shares to decline 44.8% to $1.75 on May 9, 2025.

Analysis

Iovance Biotherapeutics (NASDAQ: IOVA) faces a significant challenge with the filing of a securities class action lawsuit following a tumultuous commercial launch of its key product, Amtagvi. The lawsuit, covering the period from May 9, 2024, to May 8, 2025, alleges that the company and its leadership made materially false and misleading statements regarding Amtagvi's market introduction. Specifically, Iovance is accused of failing to disclose operational headwinds, including extended timelines for new Authorized Treatment Centers (ATCs) to initiate patient treatment, inefficiencies in patient identification and selection by both the sales team and new ATCs, and consequently, higher patient drop-off rates. These issues purportedly led to increased costs and substantially lower revenue than represented. The situation came to a head on May 8, 2025, when Iovance reported Q1 2025 total product revenue of $49.3 million, a sharp decline from the $73.7 million recorded in the prior quarter. Concurrently, the company drastically revised its FY25 total product revenue guidance downwards from an initial range of $450-$475 million to $250-$300 million, attributing the revision to "recent launch dynamics" and experiences with ATC growth and treatment timelines. This news triggered a severe market reaction, with Iovance shares plummeting 44.8% to close at $1.75 per share on May 9, 2025, amidst unusually heavy trading volume, reflecting an extremely negative investor sentiment and significant market impact.

Key Decisions for Investors

• Investors should critically re-evaluate Iovance's near-term revenue generation capability and cost structure given the Q1 2025 revenue of $49.3 million and the substantial reduction in FY25 Amtagvi revenue guidance to $250-$300 million.
• Closely monitor the progress of the securities class action lawsuit and any further disclosures from management regarding the operational challenges impacting Amtagvi's commercial ramp-up, as these will be key determinants of future performance.
• Exercise extreme caution with new or existing positions due to the significant operational headwinds, legal overhang, and substantial stock price depreciation; shareholders who acquired IOVA securities between May 9, 2024, and May 8, 2025, should assess their eligibility and options concerning the class action.